Study: Hip Surgery Readmissions Could Cost Hospitals $11k if CMS Doesn’t Pay

Each Medicare hip surgery readmission could cost a hospital an average net loss of $11,494 if CMS stops reimbursing for them, according to a study in The Journal of Arthroplasty.

Advertisement

A study of 1,583 consecutive primary total hip arthroplasty cases at one hospital yielded a 6.51 percent 30-day readmission rate. Patients with increased age, length of stay and body mass index had a higher likelihood of being readmitted, and the most common readmission diagnoses were deep infection, pain and hematoma.

The average profit for hip surgeries with readmissions was $1,548, compared with $2,872 for cases without a readmission. The hospital would have had a net loss of $11,494 if CMS did not reimburse for hip surgery readmissions, and it would need to keep its readmission rate less than 23.6 percent to remain profitable, according to the study.

More Articles on Hospital Readmissions:

Ohio State, Columbus Neighborhood Health Centers Partner to Reduce Cardiac Readmissions
Study: Readmission Risk Predicted by Composite Patient Measure
RWJF: Monetary Incentives Are Not Readmissions’ Fundamental Answer

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

When nurses help build the AI, adoption follows: Lessons from 3 health systems

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Amy McCarthy, DNP, RNC-MNN, NE-BC, CENP, Hippocratic AIBeth Reimschissel, PhD, RN, CNL, Memorial HermannAllison Schlinkert, MSN, RN, NPD-BC, Cincinnati Children'sScott Estep, MBOE, BSN, RN, CSSBB, OhioHealth System

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.